BioNTech is losing its chief strategy officer, with Ryan Richardson set to leave the company at the end of September to ...

List today: Mission Produce, Inc. AVO: This fruits producer has seen the Zacks Consensus Estimate for its current year ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, July 29th: GDS Holdings Limited GDS: This data center operator from China has a Zacks Rank #1 ...

New research by Turkish scientists has found that Pfizer’s Covid-19 vaccine may be associated with subtle changes to the ...

BioNTech has announced that it will be expanding its messenger RNA (mRNA) capabilities by acquiring CureVac for approximately $1.25bn. The deal is aimed at strengthening BioNTech’s research, ...

BioNTech will expand its pipeline into antibody-drug conjugates (ADCs) and deepen its presence in oncology through an up-to-$1.67 billion collaboration with Duality Biologics (DualityBio).

Shares in BioNTech, which is also developing cancer treatments, were down 6.7% to hit a two-month low in Frankfurt. Its US-listed shares fell 5% in premarket trading, while Pfizer's shares fell 3.5%.

BioNTech has 10 products which are in phase 2 and phase 3 trials. When asked about R&D funding, Holstein said that the company feels “comfortable” with the $2.4 billion to $2.6 billion it is ...

BioNTech will hold exclusive worldwide commercialization rights for any products it develops from these candidates, with OncoC4 participating in certain markets, which are to be negotiated in the ...

BioNTech and Pfizer had previously said they could make about 2 billion pandemic shots this year, enough to immunise 1 billion people. Next year, the partners could have capacity to make 3 billion ...

BioNTech SE has signed a definitive agreement to acquire Biotheus, a clinical-stage biotech company, with the goal of enhancing its oncology strategy. The acquisition includes access to BNT327/PM8002, ...

BioNTech and Duality Biologics have expanded their existing agreement to include a third antibody-drug conjugate (ADC) for solid tumours. The companies announced the first deal covering two ADCs in ...